Anti-Hepatitis B Virus Core Antigen antibody (ab115992)
Key features and details
- Rabbit polyclonal to Hepatitis B Virus Core Antigen
- Suitable for: IHC-P, IHC-Fr
- Reacts with: Hepatitis B virus
- Isotype: IgG
Overview
-
Product name
Anti-Hepatitis B Virus Core Antigen antibody
See all Hepatitis B Virus Core Antigen primary antibodies -
Description
Rabbit polyclonal to Hepatitis B Virus Core Antigen -
Host species
Rabbit -
Specificity
Serotype specificity information is not available for this antibody
-
Tested applications
Suitable for: IHC-P, IHC-Frmore details -
Species reactivity
Reacts with: Hepatitis B virus -
Immunogen
Full length native protein (purified) corresponding to Hepatitis B Virus Core Antigen.
-
Positive control
- Human liver tissue infected with Hepatitis B virus.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 1.17% Sodium chloride, 0.16% Sodium phosphate -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab115992 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/200 - 1/400.
|
|
IHC-Fr |
1/200 - 1/400.
|
Notes |
---|
IHC-P
1/200 - 1/400. |
IHC-Fr
1/200 - 1/400. |
Target
-
Relevance
Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection. The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection. -
Cellular localization
Capsid protein: Virion. Host cytoplasm, hepatocyte nucleus. -
Database links
- Entrez Gene: 2828293 Hepatitis B virus
- Entrez Gene: 944568 Hepatitis B virus
- SwissProt: P03146 Hepatitis B virus
- SwissProt: P03147 Hepatitis B virus
- SwissProt: P03148 Hepatitis B virus
- SwissProt: P0C573 Hepatitis B virus
- SwissProt: P69706 Hepatitis B virus
-
Alternative names
- C antibody
- Capsid protein antibody
- Core and e antigen antibody
see all
Datasheets and documents
-
Datasheet download
References (10)
ab115992 has been referenced in 10 publications.
- Vermes T et al. An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. Anal Methods 14:135-146 (2022). PubMed: 34918017
- Li B et al. Inhibition of Protease Activated Receptor 2 Attenuates HBx-Induced Inflammation and Mitochondria Oxidative Stress. Infect Drug Resist 15:961-973 (2022). PubMed: 35299854
- Clark MP et al. Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. Cell Death Dis 12:641 (2021). PubMed: 34162831
- Balagopal A et al. Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. JCI Insight 5:N/A (2020). PubMed: 33004689
- Kusama K et al. Hepatitis B Virus-related Vasculitic Neuropathy in an Inactive Virus Carrier Treated with Intravenous Immunoglobulin. Intern Med 59:3075-3078 (2020). PubMed: 32759579
- Ye L et al. Short hairpin RNA attenuates liver fibrosis by regulating the PPAR-? and NF-?B pathways in HBV-induced liver fibrosis in mice. Int J Oncol 57:1116-1128 (2020). PubMed: 33491741
- Liu J et al. Pathological Pattern of Intrahepatic HBV in HCC is Phenocopied by PDX-Derived Mice: a Novel Model for Antiviral Treatment. Transl Oncol 12:1138-1146 (2019). PubMed: 31202090
- Corcuera A et al. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro. Antiviral Res 158:135-142 (2018). PubMed: 30031759
- Chen K et al. Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity. Cell 170:492-506.e14 (2017). PubMed: 28753426
- Wang Y et al. Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC-targeting protein. J Viral Hepat 23:798-804 (2016). PubMed: 27126208